Cargando…

Metronomic Chemotherapy in Prostate Cancer

Despite the significant expansion of the therapeutic armamentarium associated with the introduction of novel endocrine therapies, cytotoxic agents, radiopharmaceuticals, and PARP inhibitors, progression of metastatic castration-resistant prostate cancer (mCRPC) beyond treatment options remains the l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wysocki, Piotr J., Lubas, Maciej T., Wysocka, Malgorzata L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143236/ https://www.ncbi.nlm.nih.gov/pubmed/35628979 http://dx.doi.org/10.3390/jcm11102853

Ejemplares similares

Metronomic Chemotherapy
por: Cazzaniga, Marina Elena, et al.
Publicado: (2021)

Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review
por: Parshad, Shruti, et al.
Publicado: (2022)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

Head and neck cancer: metronomic chemotherapy
por: De Felice, Francesca, et al.
Publicado: (2015)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Dickinson, P D, et al.
Publicado: (2012)

Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Khan, O A, et al.
Publicado: (2012)

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
por: Cazzaniga, M. E., et al.
Publicado: (2017)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer
por: Kubota, Hiroki, et al.
Publicado: (2017)

Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer
por: Liu, Jiaxuan, et al.
Publicado: (2022)

Metronomic chemotherapy: changing the paradigm that more is better
por: Scharovsky, O.G., et al.
Publicado: (2009)

Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience
por: Simsek, Cem, et al.
Publicado: (2019)

Antibody–drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management
por: Sarangi, Sudhir Chandra, et al.
Publicado: (2020)

Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies
por: Banchi, Marta, et al.
Publicado: (2022)

Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors
por: Muraro, Elena, et al.
Publicado: (2023)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

Metronomic palliative chemotherapy in maxillary sinus tumor
por: Patil, Vijay M., et al.
Publicado: (2016)

Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer
por: Koltai, Tomas, et al.
Publicado: (2019)

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
por: Perroud, Herman Andrés, et al.
Publicado: (2017)

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
por: Cazzaniga, Marina Elena, et al.
Publicado: (2022)

Role of Muscarinic Acetylcholine Receptors in Breast Cancer: Design of Metronomic Chemotherapy
por: Sales, María E., et al.
Publicado: (2019)

Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives
por: Panthi, Vijay Kumar, et al.
Publicado: (2023)

Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2016)

Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients
por: Jung, Yun Hwa, et al.
Publicado: (2017)

Can a rational design for metronomic chemotherapy dosing be devised?
por: Maraveyas, A, et al.
Publicado: (2005)

Cyclic Metronomic Chemotherapy for Pediatric Tumors: Six Case Reports and a Review of the Literature
por: Carcamo, Benjamin, et al.
Publicado: (2022)

Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas
por: Sheng Sow, Heng, et al.
Publicado: (2013)

A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells
por: Kareva, Irina
Publicado: (2017)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key
por: Rabanal, Connie, et al.
Publicado: (2017)

Metronomic chemotherapy with cyclophosphamide for the treatment of advanced hepatocellular cancer: A case report
por: Peristeri, Dimitra V., et al.
Publicado: (2021)

Metronomic Chemotherapy for Palliative Treatment of Malignant Oral Tumors in Dogs
por: Milevoj, Nina, et al.
Publicado: (2022)

Use of metronomic chemotherapy in the management of a cat with abdominal haemangiosarcoma
por: Yee-Ka Cheng, Katrina, et al.
Publicado: (2018)

Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
por: Maharjan, Ruby, et al.
Publicado: (2019)

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?
por: Kim, Do Young
Publicado: (2017)

Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
por: Al-Sukhun, Sana, et al.
Publicado: (2023)

Metronomic chemotherapy for indolent T‐cell lymphoproliferative disorder of the gastrointestinal tract
por: Liu, Hailing, et al.
Publicado: (2023)

De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?
por: Fedele, Palma, et al.
Publicado: (2021)

The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients
por: Koumarianou, Anna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1ptkokcstmsmpck4ohmlc3m98v